AiCuris is an international clinical-stage biopharmaceutical company, dedicated to the development of novel, therapeutic candidates for the prevention and treatment of severe and potentially life-threatening infectious diseases in immunocompromised patients.
The Company is focused on advancing its highly differentiated product portfolio, leveraging its research and clinical development expertise to bring game-changing, high growth potential product candidates to the market and thereby to vulnerable patients with a high need for anti-infectives treatment options.
With a solid financial position and highly experienced management team, AiCuris is on its way to becoming a fully integrated biopharmaceutical company covering the entire value chain from research through clinical development to commercialization.